Clinical Data

1. Encouraging safety profile continues with zero cases of intraocular inflammation after 420 doses in 130 patients
2. Strong anti-VEGF efficacy with extended dosing intervals continues to be observed across all three of the major retinal vascular diseases
   
3. 84% of wet AMD treated eyes and 76% of DME treated eyes extended to four months or longer before first retreatment
4. 55% of wet AMD eyes extended to six months and 64% of DME eyes extended to six months or longer